Form 4: Fulcrum CFO Granted 170,000 Stock Options

Fulcrum Therapeutics' Chief Financial Officer, Alan A Musso, was granted 170,000 stock options with an exercise price of $10.72.

Summary

• Alan A Musso, Chief Financial Officer of Fulcrum Therapeutics, Inc. (FULC), was granted 170,000 stock options.
• The stock options have an exercise price of $10.72 per share.
• The options were granted on February 2, 2026.
• These options are scheduled to vest in equal quarterly installments over four years, commencing on January 1, 2026.
• Vesting is contingent upon Mr. Musso's continued service to the company.
• The expiration date for these stock options is February 1, 2036.
• Following this transaction, Mr. Musso beneficially owns 170,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine compensation event that aligns management incentives with shareholder interests, reflecting confidence in future performance without indicating any immediate operational or financial changes.

Positives

• The grant of 170,000 stock options to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $10.72 provides a clear benchmark for future stock performance that management is incentivized to exceed.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that option grants are a common form of executive compensation in the biotechnology industry, designed to align the interests of key management personnel with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options to executive officers is a standard practice across the biotech and pharmaceutical sectors, comparable to compensation structures seen at companies like Moderna or BioNTech, where long-term incentives are tied to stock performance.

Stakeholder Impact

• Shareholders: Potential for increased long-term value as executive incentives are aligned with stock performance.
• Employees (specifically CFO): Enhanced compensation package and long-term incentive.

Next Steps

• The stock options will vest in equal quarterly installments over four years, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a key executive, which is a standard compensation practice and does not provide new information warranting a change in investment recommendation. The transaction itself is not indicative of a shift in the company's fundamental outlook.

Keywords

FULC, Fulcrum Therapeutics, stock options, insider transaction, CFO, Alan Musso, Form 4, executive compensation